Telix Pharmaceuticals Limited announced the signing of a Memorandum of Understanding (MOU) to evaluate a strategic research collaboration in the United States focused on advancing integrated theranostics solutions with United Imaging Healthcare North America Inc. The companies will evaluate the combination of United Imaging Healthcare North America Inc.'s scanner platforms, software, connectivity and AI capabilities with Telix Pharmaceuticals Limited's molecular imaging portfolio and validated clinical protocols. The collaboration will explore how a unified approach can drive theranostic workflow efficiencies and standardization by enhancing integration between imaging systems and radiopharmaceutical workflows, enabling consistent, protocol-driven imaging performance across systems and sites, supporting treatment planning, monitoring, and longitudinal patient management, and advancing data-driven and AI-enabled clinical decision support tools. The collaboration will initially focus on TLX101-Px (Pixclara®1, Floretyrosine F 18) in the United States, with potential expansion into additional markets, and other Telix Pharmaceuticals Limited products and product candidates, subject to mutual agreement.

Early efforts will include scanning protocol optimization, workflow support tools development and validation, and launching pilot programs aligned with high-impact clinical applications.